Race, Medicine, and Social Justice: Pharmacogenetics, Diversity, and the Case of BiDil

Sara R. Jordan

Review of Policy Research, 2008, vol. 25, issue 1, 53-69

Abstract: In this article, I probe an example of high‐technology medicine as a case study in the problems of the regulation of advancing technology. Specifically, I address the implications of pharmacogenomics—an emerging form of population‐based health care intervention—for public policies designed to eliminate racial disparities in health. Using the case of BiDil, a historical precursor to pharmacogenetic technology, I offer a framework for further studies of high‐technology medicine in which policy analysis is part of a social review based on the justice standard of ex ante mutual advantage. It is the contention in this article that the most just and reasonable deployment of pharmacogenomics is as a compensatory tool to alleviate health disparities.

Date: 2008
References: Add references at CitEc
Citations:

Downloads: (external link)
https://doi.org/10.1111/j.1541-1338.2008.00309.x

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:bla:revpol:v:25:y:2008:i:1:p:53-69

Ordering information: This journal article can be ordered from
http://www.wiley.com/bw/subs.asp?ref=1541-132x

Access Statistics for this article

Review of Policy Research is currently edited by Christopher Gore

More articles in Review of Policy Research from Policy Studies Organization Contact information at EDIRC.
Bibliographic data for series maintained by Wiley Content Delivery ().